cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Curis Inc
50 own
50 watching
Current Price
$0.86
$0.04
(5.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
82.99M
52-Week High
52-Week High
1.77
52-Week Low
52-Week Low
0.47
Average Volume
Average Volume
0.45M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization82.99M
icon52-Week High1.77
icon52-Week Low0.47
iconAverage Volume0.45M
iconDividend Yield--
iconP/E Ratio--
What does the Curis Inc do?
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company develops CUDC-907, an oral small molecule inhibitor of histone deacetylase and phosphatidylinositol-3-kinase enzymes, which is in Phase II clinical trials for relapsed or refractory diffuse large B-cell lymphoma, as well as in Phase I clinical trials for patients with solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trials in patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in preclinical stage for the treatment of hematologic cancers; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. It is also developing Erivedge, an orally-administered small molecule hedgehog pathway inhibitor for advanced basal cell carcinoma, idiopathic pulmonary fibrosis, and myelofibrosis. The company has collaboration agreement with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Read More
How much money does Curis Inc make?
News & Events about Curis Inc.
PR Newswire
1month ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., May 5, 2023 LEXINGTON, Mass., May 5, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the...
PR Newswire
2 months ago
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire LEXINGTON, Mass., April 5, 2023 LEXINGTON, Mass., April 5, 2023 /PRNewswire/ --Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the...
PR Newswire
2 months ago
Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call PR Newswire LEXINGTON, Mass., March 8, 2023 LEXINGTON, Mass., March 8, 2023 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused...
Benzinga
2 months ago
read more...
Frequently Asked Questions
Frequently Asked Questions
What is Curis Inc share price today?
plus_minus_icon
Can Indians buy Curis Inc shares?
plus_minus_icon
How can I buy Curis Inc shares from India?
plus_minus_icon
Can Fractional shares of Curis Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Curis Inc stocks?
plus_minus_icon
What is today’s traded volume of Curis Inc?
plus_minus_icon
What is today’s market capitalisation of Curis Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Curis Inc?
plus_minus_icon
What percentage is Curis Inc down from its 52-Week High?
plus_minus_icon
What percentage is Curis Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.86
$0.04
(5.01%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Cardiff Oncology Inc
Cardiff Oncology Inc
$1.63
$0.05 (3.16 %)
Organovo Holdings Inc
Organovo Holdings Inc
$1.72
$0.08 (4.88 %)
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc
$0.75
$0.06 (7.91 %)
AxoGen, Inc.
AxoGen, Inc.
$8.84
$0.20 (2.31 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Cardiff Oncology Inc
Cardiff Oncology Inc
$1.63
$0.05 (3.16 %)
Organovo Holdings Inc
Organovo Holdings Inc
$1.72
$0.08 (4.88 %)
Accelerate Diagnostics Inc
Accelerate Diagnostics Inc
$0.75
$0.06 (7.91 %)
AxoGen, Inc.
AxoGen, Inc.
$8.84
$0.20 (2.31 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00